Video
Author(s):
Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.
Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.
It is a challenge to determine which drug a patient should receive next, which is why it is important to have a discussion with the patient, states Hoffman-Censits.
The more researchers understand which type of bladder cancer responds to which treatment, the better selections will be made for each individual patient, explains Hoffman-Censits.